NTLA Annual Cash & Cash Equivalents
$226.75 M
-$296.76 M-56.69%
31 December 2023
Summary:
As of January 23, 2025, NTLA annual cash & cash equivalents is $226.75 million, with the most recent change of -$296.76 million (-56.69%) on December 31, 2023. During the last 3 years, it has risen by +$66.73 million (+41.70%). NTLA annual cash & cash equivalents is now -56.69% below its all-time high of $523.51 million, reached on December 31, 2022.NTLA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NTLA Quarterly Cash And Cash Equivalents
$120.50 M
-$10.35 M-7.91%
30 September 2024
Summary:
As of January 23, 2025, NTLA quarterly cash and cash equivalents is $120.50 million, with the most recent change of -$10.35 million (-7.91%) on September 30, 2024. Over the past year, it has dropped by -$47.53 million (-28.29%). NTLA quarterly cash and cash equivalents is now -76.98% below its all-time high of $523.51 million, reached on December 31, 2022.NTLA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NTLA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.7% | -28.3% |
| 3 y3 years | +41.7% | -64.0% |
| 5 y5 years | +285.3% | +213.5% |
NTLA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.7% | +83.7% | -77.0% | at low |
| 5 y | 5-year | -56.7% | +296.2% | -77.0% | +110.6% |
| alltime | all time | -56.7% | +2203.2% | -77.0% | +213.5% |
Intellia Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $120.50 M(-7.9%) |
| June 2024 | - | $130.85 M(-23.9%) |
| Mar 2024 | - | $171.98 M(-24.2%) |
| Dec 2023 | $226.75 M(-56.7%) | $226.75 M(+34.9%) |
| Sept 2023 | - | $168.03 M(-2.2%) |
| June 2023 | - | $171.81 M(-41.6%) |
| Mar 2023 | - | $294.15 M(-43.8%) |
| Dec 2022 | $523.51 M(+324.2%) | $523.51 M(+270.8%) |
| Sept 2022 | - | $141.19 M(-4.5%) |
| June 2022 | - | $147.78 M(+10.8%) |
| Mar 2022 | - | $133.38 M(+8.1%) |
| Dec 2021 | $123.41 M(-22.9%) | $123.41 M(-63.1%) |
| Sept 2021 | - | $334.74 M(+157.7%) |
| June 2021 | - | $129.88 M(-8.2%) |
| Mar 2021 | - | $141.54 M(-11.5%) |
| Dec 2020 | $160.02 M | $160.02 M(-11.0%) |
| Sept 2020 | - | $179.75 M(-50.3%) |
| June 2020 | - | $361.69 M(+346.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $80.99 M(+41.5%) |
| Dec 2019 | $57.23 M(-2.8%) | $57.23 M(+48.9%) |
| Sept 2019 | - | $38.44 M(-21.8%) |
| June 2019 | - | $49.14 M(+4.3%) |
| Mar 2019 | - | $47.10 M(-20.0%) |
| Dec 2018 | $58.86 M(-82.7%) | $58.86 M(-79.9%) |
| Sept 2018 | - | $293.25 M(-4.0%) |
| June 2018 | - | $305.54 M(-6.8%) |
| Mar 2018 | - | $327.78 M(-3.8%) |
| Dec 2017 | $340.68 M(+24.8%) | $340.68 M(+53.3%) |
| Sept 2017 | - | $222.26 M(-7.8%) |
| June 2017 | - | $241.05 M(-6.4%) |
| Mar 2017 | - | $257.55 M(-5.7%) |
| Dec 2016 | $273.06 M(+260.2%) | $273.06 M(-6.0%) |
| Sept 2016 | - | $290.62 M(-3.3%) |
| June 2016 | - | $300.69 M(+368.4%) |
| Mar 2016 | - | $64.19 M(-15.3%) |
| Dec 2015 | $75.82 M(+670.1%) | $75.82 M |
| Dec 2014 | $9.85 M | - |
FAQ
- What is Intellia Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Intellia Therapeutics?
- What is Intellia Therapeutics annual cash & cash equivalents year-on-year change?
- What is Intellia Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Intellia Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of NTLA is $226.75 M
What is the all time high annual cash & cash equivalents for Intellia Therapeutics?
Intellia Therapeutics all-time high annual cash & cash equivalents is $523.51 M
What is Intellia Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, NTLA annual cash & cash equivalents has changed by -$296.76 M (-56.69%)
What is Intellia Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NTLA is $120.50 M
What is the all time high quarterly cash and cash equivalents for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly cash and cash equivalents is $523.51 M
What is Intellia Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, NTLA quarterly cash and cash equivalents has changed by -$47.53 M (-28.29%)